- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04241029
Boosting Biologics in UC
Boosting Biologics in Ulcerative Colitis
This study evaluates the safety of the probiotic compound IDOFORM TRAVEL® in patients with ulcerative colitis undergoing anti-TNF treatment with insufficient clinical response. Furthermore, the study aims to explore the composition of the bacteria of the gut as well as the immunological activity in patients with ulcerative colitis undergoing anti-TNF treatment, aiming to identify differences between groups of patients responding and not responding adequately to treatment.
The project will explore whether probiotics have beneficial effects as adjuvant therapy in ulcerative colitis patients with insufficient response to anti-TNF treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The use of anti TNF agents has improved the medical treatment of ulcerative colitis (UC). However, one third of patients receiving such treatment will not reach remission. Studies have demonstrated that the gut microbiome influences the cytokine response and in particular the TNF production. In this study we aim to manipulate the gut microbiome in patients with ulcerative colitis not responding to anti-TNF therapy to evaluate potential beneficial effects.
20 UC patients with insufficient response to anti-tumor necrosis factor (anti-TNF) therapy upon routine evaluation colonoscopy 6-12 months after start of treatment will receive intervention with the probiotic formula IDOFORM Travel®, 4 capsules daily for 8 weeks. A colonoscopy will be performed at baseline (week 0) and after intervention (week8). Gut biopsies, fecal samples and serological markers will, in addition to clinical examination and endoscopic results, be used to evaluate the safety and possible beneficial effects of the intervention.
In a subsidiary cross-sectional study, 20 UC patients on anti-TNF therapy in remission upon evaluation colonoscopy will serve as controls. 20 individuals with no history of inflammatory bowel disease will be recruited as healthy controls.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jonas Lundekvam, MD
- Phone Number: +47 45282558
- Email: jonasalu@gmail.com
Study Locations
-
-
-
Oslo, Norway
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects may be included as cases in the study if they meet all of the following criteria:
- Diagnosed With ulcerative colitis based on Lennard-Jones criteria
- Under treatment With anti-TNF infusions/injections defined as infliximab or adalimumab
- Failure to Reach remission upon routine evaluation colonoscopy after 6-12 months of treatment - defined as an endoscopy sub score of ≥ using the Mayo score for ulcerative colitis
- Age 18-75
- Signed informed consent and expected Cooperation of the patients for the treatment and follow up must be obtained and documented according to International Committee on Harmonization (ICH) Good Clinical Practice (GCP), and national/local regulations.
Subjects may be included as Control subjects in the sub-study if they meet all of the following criteria:
- Diagnosed With ulcerative colitis based on Lennard-Jones Criteria
- Under treatment With anti-TNF infusions/injections defined as infliximab or adalimumab
- Remission upon routine colonoscopy after 6-12 months of treatment - defined as an endoscopy sub score of ≤ using the Mayo score for ulcerative colitis
- Age 18-75
- Signed informed consent and expected Cooperation of the patients for the treatment and follow up must be obtained and documented according to International Committee on Harmonization (ICH) Good Clinical Practice (GCP), and national/local regulations.
OR if they meet all the following criteria:
- No history of inflammatory bowel disease
- Age 18-75
- Signed informed consent and expected Cooperation of the patients for the treatment and follow up must be obtained and documented according to International Committee on Harmonization (ICH) Good Clinical Practice (GCP), and national/local regulations.
Exclusion Criteria:
- Clinical status poor to such extent that treating physician finds refraining from escalation of treatment contraindicated
- Signs of severe ulcerative colitis as defined by the "Montreal classification of severity of ulcerative colitis" = 3: Passage of at least six bloody stools daily, pulse rate of at least 90 beats per minute, temperature of at least 37.5°C, haemoglobin of less than 10.5 g/100 ml, and erythrocyte sedimentation rate (ESR) of at least 30 mm/h.
- Previous use of anti-TNF medication
- History of bowel resection, other inflammatory bowel disease (IBD)-related surgery, or other major intestinal surgery
- Plasma hepatitis C (HCV) positive
- Serum hepatitis B surface antigen (HBsAg) positive
- HIV positive
- Comorbidity of coeliac disease or malnutrition
- Pregnancy
- Concomitant use of non-steroid anti-inflammatory drugs (NSAIDS) or corticosteroids
- Concomitant use of antithrombotic pharmaceutical substances
- Regular (weekly) use of any probiotic substance within 3 months prior to inclusion
- Use of antibiotics within 3 months prior to inclusion
- Deranged liver function (serum albumin < 25 g/L or Child-Pugh ≥10)
- Renal failure (estimated glomerular filtration rate (eGFR) < 30
- Heart failure (NYHA class II-IV)
- Any reason why, in the opinion of the investigator, the patient should not participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention with probiotics
Intervention with the probiotic compound IDOFORM®Travel.
The patient will receive four capsules orally every 24 hour (12*10^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment.
The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
|
Four capsules IDOFORM®Travel orally every 24 hour (12*10^9 cfu/day) for eight weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 8 weeks
|
Unit of Measure: Frequency
|
8 weeks
|
Total Mayo Score for Ulcerative Colitis
Time Frame: 8 weeks
|
Alterations in Total Mayo Score at time of control colonoscopy.
Minimal value=0 (best outcome), Maximal value = 12 (worst outcome)
|
8 weeks
|
Change in Fecal Calprotectin
Time Frame: 12 weeks
|
Change in Fecal Calprotectin from baseline (week 0) to end of intervention (week 8) and after intervention (week 12). Unit of measure: mg/kg |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alterations in mucosa-adherent microbial composition
Time Frame: 8 weeks
|
Exploratory analyses of microbial composition at baseline (week 0) and at end of intervention (week 8).
(Unit of Measure: Descriptive)
|
8 weeks
|
Alterations in epithelial gene expression
Time Frame: 8 weeks
|
Exploratory (Unit of Measure: Descriptive)
|
8 weeks
|
Alterations in markers of chronic inflammation / immune activation
Time Frame: 8 weeks
|
Explorative (Unit of Measure: Descriptive)
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Asle Medhus, MD, PhD, Oslo University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016/2269
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on IDOFORM®Travel
-
Temple UniversityNot yet recruitingSerious Mental Illness
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Kenya Medical Research InstituteCompletedHepatitis B | Measles | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type bKenya
-
Emory UniversityCompletedMental FatigueUnited States
-
Queen's UniversityTerry Fox FoundationCompleted
-
Wissenschaftliches Institut Bethanien e.VCompletedTravel, Sleep Related Disorder
-
Emory UniversityCenters for Disease Control and PreventionCompleted
-
Udayana UniversityNot yet recruitingBehavior, Health | Travel-Related Illness
-
PfizerDanisco/DupontWithdrawn
-
CHU de Quebec-Universite LavalUniversity of Alberta; Laval University; Dalarna University; University of GroningenUnknownAging | Mild Cognitive Impairment | Shared Decision Making | Memory ProblemsCanada, Netherlands, Sweden
-
Vanda PharmaceuticalsCompletedJet Lag DisorderUnited States